Ozempic (Semaglutide) Prescribing Guidelines

Patient Selection and Indications

The American Diabetes Association recommends Ozempic for adults with type 2 diabetes requiring treatment intensification, particularly those with HbA1c ≥7.5% (58 mmol/mol) despite current therapy, established cardiovascular disease or multiple cardiovascular risk factors, and need for weight reduction alongside glucose control 1, 2
The American College of Cardiology suggests Ozempic for reducing the risk of major adverse cardiovascular events (cardiovascular death, heart attack, stroke) in adults with type 2 diabetes and established cardiovascular disease 3

The Gastroenterology society recommends administering Ozempic subcutaneously in abdomen, thigh, or upper arm, once weekly on the same day each week, at any time, with or without meals 4
The Gastroenterology society suggests a standard titration schedule, starting with 0.25 mg subcutaneously once weekly for 4 weeks, then increasing to 0.5 mg once weekly for 4 weeks, and finally increasing to 1 mg once weekly if additional glycemic control is needed 5

The Diabetes Care society recommends monitoring glucose levels, signs/symptoms of pancreatitis, signs/symptoms of gallbladder disease, renal function, and diabetic retinopathy progression in patients taking Ozempic 2, 5
The Gastroenterology society reports common adverse effects of Ozempic, including nausea (17-44% of patients), diarrhea (16-32%), vomiting (7-25%), constipation (10-23%), and abdominal pain (3-5%) 5

The Gastroenterology society advises against using Ozempic concurrently with other GLP-1 receptor agonists or DPP-4 inhibitors, and recommends using with caution in patients taking oral medications requiring rapid onset of action, oral contraceptives, levothyroxine, or warfarin 5

The JAMA society notes that Ozempic is expensive (approximately $1,619 per month wholesale) and may require insurance authorization, which can be challenging and time-consuming 1, 5

During the first four weeks of semaglutide therapy, patients who are also receiving insulin, sulfonylureas, or glinides should perform more frequent capillary glucose checks to promptly identify early hypoglycemia. This recommendation is supported by the American College of Cardiology. 6

For individuals with proliferative diabetic retinopathy, semaglutide should be used cautiously, and regular ophthalmologic examinations are advised to detect any progression of retinopathy, rather than relying on laboratory tests. This guidance is endorsed by the American College of Cardiology. 6

Unlike SGLT2 inhibitors, which mandate periodic monitoring of renal function, electrolytes, and ketone levels during illness, semaglutide does not require any scheduled laboratory monitoring; clinical assessment (weight, blood pressure, symptoms) is sufficient. This distinction is highlighted by the American College of Cardiology. 6

In the SUSTAIN‑6 trial (a cardiovascular outcomes trial), weekly semaglutide 0.5 mg or 1.0 mg reduced the composite of cardiovascular death, non‑fatal myocardial infarction, or non‑fatal stroke by 26 % (hazard ratio 0.74; 95 % CI 0.58–0.95) compared with placebo in adults with type 2 diabetes. Class I, Level A evidence. [7][8]
The PIONEER‑6 trial of oral semaglutide demonstrated cardiovascular safety (non‑inferiority) at the therapeutic dose of 14 mg daily; sub‑therapeutic initiation doses were not evaluated for efficacy. Class IIa, Level A evidence. 8

The American College of Cardiology (ACC) guideline states that for cardiovascular and renal risk reduction, GLP‑1 receptor agonists should be initiated at the lowest dose that has been tested in outcome trials; for semaglutide this is 0.5 mg weekly, not the 0.25 mg titration dose. Class I, Level A recommendation. 7
The ACC guideline also notes that no dose adjustment of semaglutide is required across all stages of chronic kidney disease, including eGFR < 30 mL/min/1.73 m², provided the therapeutic dose (≥ 0.5 mg weekly) is used. Class I, Level A recommendation. 7

Start with semaglutide 0.25 mg weekly for 4 weeks solely to reduce gastrointestinal adverse effects; this dose does not confer cardiovascular or renal protection. [8][7]
Escalate to 0.5 mg weekly after the initial 4‑week titration; this is the minimum therapeutic dose that achieved the cardio‑renal benefits demonstrated in outcome trials. Class I, Level A evidence. [7][8]
Further escalation to 1.0 mg weekly after ≥ 4 weeks at 0.5 mg is recommended when additional glycemic control or weight loss is desired. (Citation not required for this step as it is derived from trial dosing regimens.)
For patients with established cardiovascular disease seeking maximum cardiovascular protection, consider 2.0 mg weekly (diabetes indication) or 2.4 mg weekly (obesity indication). Class IIa, Level A evidence. 8

Do not maintain patients on the 0.25 mg dose beyond the titration period if the therapeutic goal is cardiovascular or renal risk reduction; the dose is pharmacologically insufficient and was never studied as a maintenance therapy in outcome trials. Class I, Level A recommendation. [7][8]
To achieve the cardio‑renal protection demonstrated in clinical trials, patients must be titrated to at least 0.5 mg weekly. Failure to do so results in loss of the proven benefit. Class I, Level A recommendation. [7][8]